Mechanisms of Anti-VEGF Therapies in Retinal Vascular Diseases

This episode, titled “Mechanisms of Anti-VEGF Therapies in Retinal Vascular Diseases,” features panelists discussing the mechanistic differences between next-generation anti-VEGF therapies and how these innovations may influence disease control and treatment durability in retinal vascular diseases. The panel explores how newer therapies are being designed to improve upon first-generation anti-VEGF agents through higher molar dosing, novel mechanisms of action, and enhanced pharmacokinetic properties.

The expert faculty review the rationale behind aflibercept 8 mg, highlighting how increased molar dosing may contribute to faster disease control and improved durability compared with earlier-generation formulations. The discussion also examines faricimab’s dual inhibition of VEGF-A and angiopoietin-2 (ANG-2), including how targeting multiple biologic pathways may influence vascular leakage, inflammation, and long-term disease management.

Throughout the conversation, the panel discusses how advances in pharmacokinetics and pharmacodynamics are shaping the development of newer anti-VEGF therapies and potentially extending treatment intervals for patients with neovascular age-related macular degeneration (AMD), diabetic macular edema (DME), and retinal vein occlusion (RVO). The panelists also highlight the importance of balancing efficacy, durability, and safety when evaluating emerging retinal therapies. In addition, the discussion emphasizes how these mechanistic advancements may help optimize disease control, reduce treatment burden, and improve long-term outcomes for patients living with retinal vascular diseases.

In the next episode, “Clinical Trial Insights in Retinal Vascular Diseases,” panelists will discuss pivotal clinical trial data evaluating aflibercept 8 mg and faricimab across AMD, DME, and RVO. The expert faculty will also highlight how durability, safety, fluid control, and extended dosing intervals are influencing treatment selection and long-term disease management in retinal vascular diseases.